Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Revenue increased 11.4 per cent to Rs. 8,545 crore
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
The USFDA inspectors issued the observations after a product pre-approval inspection of the biologics facility in Bachupally
The inspection closed with zero observations
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Subscribe To Our Newsletter & Stay Updated
